Acta Pharmaceutica Sinica B

期刊官网投稿通道

提出问题

友情提示：以下期刊信息可能会有更新，仅供参考，请在投稿前自行登录期刊官网仔细核实。

期刊名

Acta Pharmaceutica Sinica B

ACTA PHARM SIN B

ISSN / eISSN

2211-3835 / 2211-3843

目标和范围

Acta Pharmaceutica Sinica B (APSB) is a bimonthly journal, in English, which publishes significant original research articles, rapid communications and high quality reviews of recent advances in all areas of pharmaceutical sciences — including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics.

研究方向

药学

CiteScore

19.40

查看趋势图

CiteScore 学科排名

类别	分区	排名
Pharmacology, Toxicology and Pharmaceutics - General Pharmacology, Toxicology and Pharmaceutics	Q1	#1/79

Web of Science 核心合集

Science Citation Index Expanded (SCIE)	Social Sciences Citation Index (SSCI)
Indexed	-

类别 (Journal Citation Reports 2023)	分区
PHARMACOLOGY & PHARMACY - SCIE	Q1

H-index

出版国家或地区

Netherlands

出版商

Elsevier BV

年文章数

281

Open Access

YES

通讯方式

C/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST, BEIJING, PEOPLES R CHINA, 100050

同领域相关热门期刊
近期发表文章

Traditional Chinese medicine for the treatment of immune-related nephropathy: a review: (2023) Pu Jiang, Changliang Yao, De-an Guo

Biomimetic “gemini nanoimmunoregulators” orchestrated for boosted photoimmunotherapy by spatiotemporally modulating PD-L1 and tumor-associated macrophages: (2023) Honglin Huang, Ningxi Li, Xiaodan Wei, Qingzhi Li, Junhan Guo, Geng Yang, Hong Yang, Lulu Cai, Yiyao Liu, Chunhui Wu

A novel deep generative model for mRNA vaccine development: Designing 5ʹ UTRs with N1-methyl-pseudouridine modification: (2023) Xiaoshan Tang, Miaozhe Huo, Yuting Chen, Hai Huang, Shugang Qin, Jiaqi Luo, Zeyi Qin, Xin Jiang, Yongmei Liu, Xing Duan, Ruohan Wang, Lingxi Chen, Hao...

Towards overcoming obstacles of Type II photodynamic therapy: Endogenous production of light, photosensitizer, and oxygen: (2023) Lin Yu, Zhen Liu, Wei Xu, Kai Jin, Jinliang Liu, Xiaohui Zhu, Yong Zhang, Yihan Wu

Targeting FAPα-positive lymph node metastatic tumor cells suppresses colorectal cancer metastasis: (2023) Shuran Fan, Ming Qi, Qi Qi, Qun Miao, Lijuan Deng, Jinghua Pan, Shenghui Qiu, Jiashuai He, Maohua Huang, Xiaobo Li, Jie Huang, Jiapeng Lin, Wenyu Lyu,...

Development of Chinese herbal medicine for sensorineural hearing loss: (2023) Yunhao Wu, Jingwen Zhang, Qiuping Liu, Zhuang Miao, Renjie Chai, Wenyong Chen

Epigenetic modification in liver fibrosis: Promising therapeutic direction with significant challenges ahead: (2023) Runping Liu, Yajing Li, Qi Zheng, Mingning Ding, Huiping Zhou, Xiaojiaoyang Li

Broad-spectrum ginsentides are principal bioactives in unraveling the cure-all effects of ginseng: (2023) Shining Loo, Antony Kam, Bamaprasad Dutta, Xiaohong Zhang, Nan Feng, Siu Kwan Sze, Chuan-Fa Liu, Xiaoliang Wang, James P. Tam

Tumor-targeted metabolic inhibitor prodrug labelled with cyanine dyes enhances immunoprevention of lung cancer: (2023) Wen Li, Jiali Huang, Chen Shen, Weiye Jiang, Xi Yang, Jingxuan Huang, Yueqing Gu, Zhiyu Li, Yi Ma, Jinlei Bian

High-throughput screening of novel TFEB agonists in protecting against Acetaminophen-Induced Liver Injury in Mice: (2023) Xiaojuan Chao, Mengwei Niu, Shaogui Wang, Xiaowen Ma, Xiao Yang, Hua Sun, Xujia Hu, Hua Wang, Li Zhang, Ruili Huang, Menghang Xia, Andrea Ballabio, Ha...

认证评论

注：认证评论选取于全球各个学术评论平台和社交媒体。

2021.6 ACS Nano tragedy of submission (2 accepted, 1 rejected), Argue got rejected, took half a year.
2022.2.19 Submit APSB
2022.2.24 Under Review
2022.3.11 Revision (The questions raised by the three reviewers were crucial, and they provided excellent constructive feedback. They were very professional and gave high praise. The quality of the paper also improved significantly.)
2022.4.7 Revision Submitted
2022.4.9-4.22 Status with editor-decision in progress-under review-review completed-decision nerve-wracking
2022.5.7 Accept
The speed was much faster compared to before. Thanks to all the editors and reviewers at APSB. I wish domestic journals continued to improve!

2022-05-07

The self-citation rate is calculated as a percentage based on (1 - IF without self-citation / IF). In 2021, the "without self-citation" component of this journal's SCI IF is definitely problematic and needs to be recalculated after the data is corrected. One can only wonder why Clarivate Analytics didn't perform any abnormal data validation for such a simple error...

2021-10-09

查看所有评论

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started